Facility Trends: Modularization and Single Use - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Facility Trends: Modularization and Single Use
Pharmaceutical Technology spoke with INTERPHEX 2013 conference-session presenters to gain insight on trends in facility and process design.


Pharmaceutical Technology
Volume 37, Issue 5, pp. 76-78

PharmTech: Who should consider implementing at least some single-use systems?

Odum: Implementing single-use technology must be driven by the product and process attributes, the need for flexibility, and an understanding of the critical process parameters. Any number of manufacturing organizations could benefit from the implementation of single-use technology.

One group that I think is going to see a significant benefit is contract manufacturers. Because their business model is driven by both speed and flexibility, single-use technology could provide some distinct advantages in terms of their ability to adapt to new processes based on not only new clients but existing clients. Single-use technology gives them the flexibility to change their platform technology rather rapidly and probably with a lower cost. Lower need for classified space would also decrease capital expenditures.

Other business models would also benefit from this type of technology. Organizations that are focused on process development, such as research-driven organizations that do high-level development work, would benefit. Manufacturers focused on pandemic response would benefit from the ability to adapt very rapidly. Flexibility and adaptability are crucial.

Another group that could benefit from single-use technology, in a way that perhaps they haven't started to look at in depth, is the academic institutions, which are being squeezed by their ability to fund capital expenditures for facility infrastructure. Any manufacturing organization should really explore the potential advantages of this type of technology.

PharmTech: What are some of the unique challenges of implementing single-use systems, particularly when you have an existing stainless-steel facility?

Odum: We work with a number of clients who have a stainless steel-based platform and are creating what we refer to as hybrid facilities. Three challenges stand out. First is a real understanding of the process definition and description. Although this may seem obvious, we have found that companies sometimes have a knowledge gap, especially from a developmental standpoint, on exactly how a specific process-unit operation may or may not be impacted by going to this technology.

The second challenge is looking at flows. Single-use systems are very flexible and modular in their approach from an equipment standpoint, and the ability to move components in and out of a particular space creates some logistical issues. As a part of that, there also needs to be a close investigation of accessibility. When your scenario includes a fixed stainless-steel asset that resides in a particular manufacturing suite—maybe due to size or maybe due to a future need—the ability for operators to access equipment and perform their day-to-day operations is extremely important.

The third challenge is process support. When you are dealing with single-use systems, you are now going to also deal with many single-use components that are absolutely necessary in order for each process unit operation to be executed and work the way it's supposed to. Tube sets, for example, are needed to connect components and allow the process to occur. Instruments, such as those to measure flow or temperature, must be integrated into the system. The design and development of these support items becomes a complex effort because there are a lot of parts and pieces that are going to have to be put together. Some companies get outside vendors to do this for them. Others have chosen to do some of it internally, but it's very different from designing a fixed piece of stainless-steel pipe in a building to run from point A to point B. Because of the fact that you're dealing with tubing, you have issues with regards to accessibility and logistics. Where do these hang? How do you support them? How do you make sure that they do not get damaged, or stepped on, or run over during the movement of equipment?

Wrapping around all these issues is the idea of closure. One of the things that we pay very close attention to is the idea of looking at system-closure analysis to make sure that, as all these components are designed, we are doing everything that is necessary to, first and foremost, protect the product from any potential contamination source and, in doing so, making sure that the system components are designed properly so that this closure can be validated.

Single-use technology is not without its challenges, but these are challenges that are being addressed to create systems that are efficient and bring a much higher utilization to a facility.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
26%
Oversee medical treatment of patients in the US.
13%
Provide treatment for patients globally.
11%
All of the above.
39%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here